[1]Geisler S, Doan RA, Cheng GC, et al. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program[J]. JCI Insight, 2019, 4(17): 1-17.
[2]Xue K, Ying X, Bu Z, et al. Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial [J]. Chin J Cancer Res, 2018, 30(5): 516-525.
[3]Seretny M, Currie GL, Sena ES,et al. Incidence, prevalence, and predictors of chemotherapy-inducedperipheral neuropathy: a systematic review and meta-analysis[J]. Pain, 2014, 155(12): 2461-2470.
[4]Khuenl KS, Sparr H. Clinical pharmacokinetics of rocuronium bromide [J]. Clin Pharmacokinet, 1996, 31(3): 174-183.
[5]Fuchs-Buder T, Claudius C, Skovgaard LT, et al. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision [J]. Acta Aaesthesiol Seand, 2007, 51(7): 789-808.
[6]Hirakawa M, Sato Y, Ohnuma H, et al. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker [J]. Cancer Chemother Pharmacol, 2013, 71: 789-797.
[7]Inoue K, Nakane Y, Kogire M, et al. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer[J]. Eur J Surg Oncol, 2012, 38: 143-149.
[8]Mathijssen RH, van Schaik RH. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment [J]. Eur J Cancer, 2006, 42(2): 141-148.
[9]沈冬,宋宇. 卡培他滨维持化疗治疗晚期胃癌和术后复发转移胃癌的安全性及预后分析[J]. 现代肿瘤医学, 2015, 23(18): 2646-2649.
[10]康定鑫,姬斌,李军. 七氟烷和地氟烷对小儿手术中罗库溴铵持续输注速率的影响[J]. 中国临床药理学杂志,2017,33(21):2120-2123.
[11]Kim YB,Lee S,Lee KC, et al. Effects of presynaptic muscarinic cholinoreceptor blockade on neuromuscular transmission as assessed by the train-of-four and the tetanic fade response to rocuronium [J]. Clin Exp Pharmacol Physiol,2017,44(7):795-802.
[12]Paris I, Cappellini GC, Malaguti P, et al. Pharmacogenomics and chemotherapy[J]. Recenti Prog Med, 2010, 101(7/8): 277-282.
[13]曹冬冬, 王吨卫, 马雯, 等. 新辅助化疗因素对胃癌根治术患者顺阿曲库铵肌松效应的影响[J]. 中华麻醉学杂志, 2017, 37(5): 588-590.
[14]赵婷, 肖春龙. 术前新辅助化疗对乳腺癌根治术患者顺式阿曲库铵肌松效应的影响[J]. 解放军医药杂志, 2018, 30(3): 44-47.
[15]冯趁霞, 刘忠民, 冯桂真, 等. 乳腺癌化疗后对肌松药维库溴铵的影响[J]. 现代医药卫生, 2017, 33(13): 1972-1976.
[16]袁晓红,方军,郭建荣, 等. 急性高容血液稀释对不同剂量罗库溴铵肌松效应的影响[J]. 中国临床药理与治疗学, 2013, 18(12): 1396-1400.
[17]Loupakis F, Masi G, Fornaro L, et al. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma[J]. Cancer Chemother Pharmacol, 2010, 66(3): 559-566.
[18]Swanson HI, Njar VC, Yu Z,et al. Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy[J]. Drug Metab Dispos, 2010, 38(4): 539-544.
[19]Amir PZ, Maziar M, Jalil M, et al. Chemotherapy alters cisatracurium induced neuromuscular blockadecharacteristics: A prospective cohort study [J]. J Clin Anesth, 2017, 36: 84-87.
[20]Allum WH, Smyth EC, Blazeby JM, et al. Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction[J]. Br J Surg, 2019, 106(9): 1204-1215. |